Stockreport

Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA

Corbus Pharmaceuticals Holdings, Inc.  (CRBP) 
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: corbuspharma.com
PDF Phase 3 primary endpoint will now be aligned with that of previous Phase 2 studyACR CRISS is a composite index (composed of multiple outcomes including mRSS) and was sec [Read more]